Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference

TORONTO--()--Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference being held on May 1 – 2, 2017 in Toronto, Canada.

Event:

    Sixth Annual Bloom Burton & Co. Healthcare Investor Conference

Location:

Hall B, Lower Concourse Level, Sheraton Centre Toronto Hotel (Toronto, Canada)

Date:

Monday, May 1st, 2017

Time:

3:30 pm (ET)
 

Antibe’s CEO, Dan Legault, will deliver the Company’s presentation and will discuss recent business highlights and its growth strategy. Antibe will also be available for one-on-one investor meetings on both days of the conference.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.

Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.

About the Conference

Bloom Burton & Co. (“Bloom Burton”) is hosting its sixth annual Healthcare Investor Conference on May 1 and 2, 2017 at the Sheraton Centre Toronto Hotel, Toronto, Canada. Bloom Burton aims to showcase approximately sixty of the premier Canadian healthcare companies to its network of investors, who generally attend from across Canada, the U.S. and Europe. The conference includes networking sessions, keynote speeches and panel discussions with venture capital, public equity and strategic investors. The event attracts investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies and participate in the 1-on-1 meeting system with company management.

Forward Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Contacts

Antibe Therapeutics Inc.
Dan Legault, 416-473-4095
Chief Executive Officer
dan.legault@antibethera.com

Release Summary

Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference

Contacts

Antibe Therapeutics Inc.
Dan Legault, 416-473-4095
Chief Executive Officer
dan.legault@antibethera.com